More importantly, we screened gemcitabine treated patients in the TCA-PAAD pancreatic cancer data set and measured their treatment efficacy, and found significantly lower ERAP2 expression values in the effective group (PR/CR) than in the ineffective group (PD) (Figure 4C). This evidence concerns the gene ERAP2 and pancreatic neoplasm.